Not really the right measure. Data is not out and bios tend to issue lots of shares to pay bills as they head to a trials conclusion and go for licensing. This was an exceptionally long trial, and it turns out that was for good reason. She could have ended it 5 years ago and just said, “You know, I was told to hold out for 5 more years, but I’ve got better things to do. See ya!”
400+ failures of very promising companies and some of the were championed by such leading lights as AF, failed completely, for GBM alone.
Looks like she and is investors have a winner in DCVax-L.
Additionally, over 5 years up something like 195%, and over 2 years 100%, and YTD basically flat, I think a lot of investors right now, given the macroeconomic situation, would call that pretty fabulous.
So yeah, there are those who blow smoke, but not really the full truth or even the partial truth in most instances. And yes, the shorting of the stock did do a lot of damage at one point, but that is not her fault. There are bad players in the markets and they love to target small bios like this one because it is easy money. Retail is easily deceived, and shorting makes a lot of money fast and easily. It’s a big transfer from the many small pockets of retail right into the treasury of robber baron hedge fund managers, who then pay that out to their investors who don’t care what evils were perpetrated in their names, just that it made them rich. It’s a fine tradition that goes back to piracy on the high seas.
Market Data 
Markets 
AI
